OMER
VENTE TOTALE: 30 000 titres (~558 167,00 $ US)
- Insiders
- HANISH ARNOLD C, Cable Thomas J.
- Total bought
- —
- Total sold
- $558,167
- Last activity
- 2026-08-27
- Last synced
-
2026-09-02 21:34:12
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-01
Despite a moderate earnings catalyst (Q2 beat, first YARTEMLEA sales), OMER's financial foundation is critically weak with zero historical revenue, extreme negative cash flows, and no viable operating model to sustain…
The first sentence of the analysis written for OMER on 2026-09-01 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 2.763 | 1.686 | 4.087 | 3.250 | 4.788 | |
| Quick Ratio | 2.763 | 1.686 | 4.087 | 3.250 | 4.788 | |
| Solvency Ratio | -0.005 | -0.339 | -0.290 | 0.096 | -0.278 | |
| Cash Ratio | 0.124 | 0.043 | 0.133 | 0.081 | 1.947 | |
| Price To Earnings Ratio | -325.996 | -3.659 | -1.739 | 4.913 | -3.592 | |
| Price To Earnings Growth Ratio | 3.325 | -0.084 | 0.003 | -0.039 | 0.140 | |
| Forward Price To Earnings Growth Ratio | 3.325 | -0.084 | 0.003 | -0.039 | 0.140 | |
| Price To Earnings Diluted Ratio | -325.996 | -3.659 | -1.739 | 4.913 | -3.592 | |
| Price To Earnings Diluted Growth Ratio | 3.325 | -0.084 | 0.003 | -0.039 | 0.140 | |
| Price To Book Ratio | -9.000 | -3.147 | -8.212 | 1.655 | 16.858 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -9.393 | -3.858 | 2.761 | -1.637 | -3.644 | |
| Price To Operating Cash Flow Ratio | -9.398 | -3.862 | 2.745 | -1.639 | -3.654 | |
| Debt To Assets Ratio | 0.734 | 0.747 | 0.956 | 0.579 | 0.830 | |
| Debt To Equity Ratio | -1.973 | -1.134 | -14.473 | 3.992 | 14.627 | |
| Debt To Capital Ratio | 2.028 | 8.481 | 1.074 | 0.800 | 0.936 | |
| Long Term Debt To Capital Ratio | 2.389 | -10.395 | 1.082 | 0.721 | 0.929 | |
| Financial Leverage Ratio | -2.686 | -1.517 | -15.141 | 6.897 | 17.631 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -1.487 | -1.871 | 1.402 | -0.634 | -2.119 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.001 | 0.994 | 1.001 | 1.003 | |
| Debt Service Coverage Ratio | -0.225 | -3.437 | -3.632 | -1.353 | -8.668 | |
| Interest Coverage Ratio | 0.000 | -6.859 | -5.334 | -7.197 | -8.827 | |
| Short Term Operating Cash Flow Coverage Ratio | -6.804 | -7.086 | 8.713 | -0.916 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.485 | -0.719 | 0.207 | -0.253 | -0.315 | |
| Capital Expenditure Coverage Ratio | -1,786.062 | -901.836 | 175.413 | -765.336 | -396.108 | |
| Dividend Paid And Capex Coverage Ratio | -1,786.062 | -901.836 | 175.413 | -765.336 | -396.108 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -720.845 | -4.958 | -3.909 | -2.985 | -3.800 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 2.763 | ▲1.076 | ▼-0.552 |
| Quick Ratio | 2.763 | ▲1.076 | ▼-0.552 |
| Solvency Ratio | -0.005 | ▲0.334 | ▲0.158 |
| Cash Ratio | 0.124 | ▲0.081 | ▼-0.342 |
| Price To Earnings Ratio | -325.996 | ▼-322.337 | ▼-259.981 |
| Price To Earnings Growth Ratio | 3.325 | ▲3.409 | ▲2.656 |
| Forward Price To Earnings Growth Ratio | 3.325 | ▲3.409 | ▲2.656 |
| Price To Earnings Diluted Ratio | -325.996 | ▼-322.337 | ▼-259.981 |
| Price To Earnings Diluted Growth Ratio | 3.325 | ▲3.409 | ▲2.656 |
| Price To Book Ratio | -9.000 | ▼-5.853 | ▼-8.631 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -9.393 | ▼-5.535 | ▼-6.239 |
| Price To Operating Cash Flow Ratio | -9.399 | ▼-5.536 | ▼-6.237 |
| Debt To Assets Ratio | 0.734 | ▼-0.013 | ▼-0.035 |
| Debt To Equity Ratio | -1.973 | ▼-0.839 | ▼-2.180 |
| Debt To Capital Ratio | 2.028 | ▼-6.452 | ▼-0.636 |
| Long Term Debt To Capital Ratio | 2.389 | ▲12.783 | ▲3.443 |
| Financial Leverage Ratio | -2.686 | ▼-1.169 | ▼-3.723 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -1.487 | ▲0.384 | ▼-0.545 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | ▼-0.001 | ▲0.001 |
| Debt Service Coverage Ratio | -0.225 | ▲3.212 | ▲3.238 |
| Interest Coverage Ratio | 0.000 | ▲6.859 | ▲5.644 |
| Short Term Operating Cash Flow Coverage Ratio | -6.804 | ▲0.282 | ▼-5.585 |
| Operating Cash Flow Coverage Ratio | -0.485 | ▲0.233 | ▼-0.172 |
| Capital Expenditure Coverage Ratio | -1786.062 | ▼-884.225 | ▼-1051.276 |
| Dividend Paid And Capex Coverage Ratio | -1786.062 | ▼-884.225 | ▼-1051.276 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -720.845 | ▼-715.888 | ▼-573.546 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.09B | $574.7M | $205.2M | $141.8M | $400.9M | |
| Enterprise value | $1.32B | $778.3M | $559.6M | $472.8M | $647.9M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -11.38x | -5.23x | 7.49x | -5.47x | -5.91x | |
| EV / Free cash flow | -11.37x | -5.22x | 7.53x | -5.46x | -5.89x | |
| EV / EBITDA | -720.85x | -4.96x | -3.91x | -2.98x | -3.80x | |
| Net debt / EBITDA | -125.26x | -1.30x | -2.48x | -2.09x | -1.45x | |
| Current ratio | 2.76x | 1.69x | 4.09x | 3.25x | 4.79x | |
| Income quality | 34.66x | 0.95x | -0.63x | 0.47x | 0.57x | |
| Graham number | — | — | — | $5 | — | |
| Graham net-net | -$4 | -$6 | -$4 | -$2 | -$3 | |
| Tax burden | 119.8% | 85.9% | 67.4% | -26.0% | 58.2% | |
| Interest burden | 100.0% | 115.6% | 121.4% | 114.2% | 111.4% | |
| Working capital | $137.6M | $54.6M | $164.6M | $306.9M | $196.2M | |
| Invested capital | $150.1M | $72.2M | $185.2M | $330.1M | $226.2M | |
| Return on assets | -1.0% | -56.6% | -31.1% | 8.0% | -26.6% | |
| Operating ROA | -40.7% | -51.7% | -34.0% | -32.3% | -57.8% | |
| Return on tangible assets | -1.0% | -56.6% | -31.1% | 8.0% | -26.6% | |
| Return on equity | 2.8% | 85.9% | 471.6% | 55.3% | -468.5% | |
| Return on invested capital | -45.3% | -75.4% | -48.6% | -29.5% | -46.6% | |
| Return on capital employed | -49.6% | -85.7% | -50.6% | -35.9% | -47.2% | |
| Earnings yield | -0.3% | -27.3% | -57.4% | 33.4% | -27.8% | |
| Free cash flow yield | -10.6% | -25.9% | 36.2% | -61.1% | -27.4% | |
| Capex / Op. cash flow | -0.1% | -0.1% | 0.6% | -0.1% | -0.3% | |
| Capex / Depreciation | 6.7% | 17.4% | 46.3% | 11.9% | 20.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 3529d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | -3529d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+89.8%EV / Sales n/aEV / EBITDA ▼-14440.5%EV / Op. cash flow ▼-6.144Earnings yield ▲+0.270
Profitability
Return on equity ▼-0.831Return on assets ▲+0.556Return on invested capital ▲+0.301Return on capital employed ▲+0.361Operating ROA ▲+0.109Income quality ▲+33.706Tax burden ▲+0.339
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+1.076Net debt / EBITDA ▼-123.967Working capital ▲+83011000.000Invested capital ▲+77848000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+172.2%EV / Sales n/aEV / EBITDA ▼-18868.5%EV / Op. cash flow ▼-5.470Earnings yield ▲+0.275
Profitability
Return on equity ▲+4.713Return on assets ▲+0.255Return on invested capital ▲+0.013Return on capital employed ▼-0.024Operating ROA ▲+0.171Income quality ▲+34.082Tax burden ▲+0.616
Efficiency
Days sales outstanding n/aDays payables outstanding ▼-3528.860Operating cycle n/aCash conversion cycle ▲+3528.860Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-2.025Net debt / EBITDA ▼-123.815Working capital ▼-58562000.000Invested capital ▼-76093000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-01 BlackRock Inc. Invests $57.48 Million in Omeros Corporation $OMER BlackRock Inc. purchased a new stake in Omeros Corporation (NASDAQ: OMER) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,044,633 shares of the biopharmaceutical company''s stock, valued at approximately $57,484,000. BlackRock Inc. owned approximately 8.35% of Omeros at the end
- 2026-08-28 What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now? Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let''s find out.
- 2026-08-25 Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy? Omeros Corporation (OMER) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, OMER''s 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
- 2026-08-15 Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Brokerages Shares of Omeros Corporation (NASDAQ: OMER - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six analysts that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the
- 2026-08-13 Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript
- 2026-08-12 Omeros Q2 Earnings Call Highlights Omeros NASDAQ: OMER reported second-quarter net sales of $28.5 million for YARTEMLEA, its newly launched treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA, as the company generated positive operating cash flow and reduced its convertible debt after the quarter ended.
- 2026-08-12 Omeros (OMER) Q2 Earnings and Revenues Beat Estimates Omeros (OMER) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to a loss of $0.53 per share a year ago.
- 2026-08-12 Omeros Corporation Reports Second Quarter 2026 Financial Results SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2026, which include: Second Quarter and Recent Highlights YARTEMLEA®, the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-lethal complication of stem cell transplantation, generated gross revenues of $32.2 million in the second quarter of 2026, an incre.
- 2026-08-10 Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026 SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the second quarter of 2026 on Wednesday, August 12, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company''s financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please.
- 2026-08-05 Omeros (NASDAQ:OMER) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened Shares of Omeros Corporation (NASDAQ: OMER - Get Free Report) crossed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $11.41 and traded as high as $13.05. Omeros shares last traded at $12.94, with a volume of 1,645,947 shares traded. Analyst Upgrades and